These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

402 related items for PubMed ID: 26994437

  • 1. Comparative effectiveness of long-acting injectable risperidone vs. long-acting injectable first-generation antipsychotics in bipolar disorder.
    Wu CS, Hsieh MH, Tang CH, Chang CJ.
    J Affect Disord; 2016 Jun; 197():189-95. PubMed ID: 26994437
    [Abstract] [Full Text] [Related]

  • 2. Clinical outcomes of long-acting injectable risperidone in patients with bipolar I disorder: A 1-year retrospective cohort study.
    Chan HW, Huang CY, Feng WJ, Yen YC.
    J Affect Disord; 2016 Nov 15; 205():360-364. PubMed ID: 27568173
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. A long-term prospective study on the outcome of bipolar patients treated with long-acting injectable risperidone.
    Vieta E, Nieto E, Autet A, Rosa AR, Goikolea JM, Cruz N, Bonet P.
    World J Biol Psychiatry; 2008 Nov 15; 9(3):219-24. PubMed ID: 18609430
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Long-acting second-generation injectable antipsychotics for the maintenance treatment of bipolar disorder: a narrative review.
    Belge JB, Sabbe BGCC.
    Expert Opin Pharmacother; 2024 Feb 15; 25(3):295-299. PubMed ID: 38465894
    [Abstract] [Full Text] [Related]

  • 8. Adjunctive long-acting risperidone in patients with bipolar disorder who relapse frequently and have active mood symptoms.
    Macfadden W, Adler CM, Turkoz I, Haskins JT, Turner N, Alphs L.
    BMC Psychiatry; 2011 Oct 28; 11():171. PubMed ID: 22034906
    [Abstract] [Full Text] [Related]

  • 9. What is the evidence for the use of second-generation antipsychotic long-acting injectables as maintenance treatment in bipolar disorder?
    Samalin L, Nourry A, Charpeaud T, Llorca PM.
    Nord J Psychiatry; 2014 May 28; 68(4):227-35. PubMed ID: 23795859
    [Abstract] [Full Text] [Related]

  • 10. Long-Acting Injectable Second-Generation/Atypical Antipsychotics for the Management of Bipolar Disorder: A Systematic Review.
    Keramatian K, Chakrabarty T, Yatham LN.
    CNS Drugs; 2019 May 28; 33(5):431-456. PubMed ID: 30963507
    [Abstract] [Full Text] [Related]

  • 11. Comparison of treatment effectiveness and medical costs for different long-acting injectable antipsychotics in patients with schizophrenia in Taiwan: A nationwide population-based cohort study.
    Wu CS, Cheng IC, Feng J, Chen CL.
    Schizophr Res; 2016 May 28; 173(1-2):37-44. PubMed ID: 26987938
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Impact of initiating long-acting injectable antipsychotics on hospitalization in patients with bipolar I disorder.
    Yan T, Greene M, Chang E, Touya M, Broder MS.
    J Comp Eff Res; 2018 Nov 28; 7(11):1083-1093. PubMed ID: 30129771
    [Abstract] [Full Text] [Related]

  • 14. Bipolar patients treated with long-acting injectable risperidone in Taiwan: A 1-year mirror-image study using a national claims database.
    Hsieh MH, Chuang PY, Wu CS, Chang CJ, Chung PF, Tang CH.
    J Affect Disord; 2017 Aug 15; 218():327-334. PubMed ID: 28494390
    [Abstract] [Full Text] [Related]

  • 15. Risperidone long-acting injectable monotherapy in the maintenance treatment of bipolar I disorder.
    Quiroz JA, Yatham LN, Palumbo JM, Karcher K, Kushner S, Kusumakar V.
    Biol Psychiatry; 2010 Jul 15; 68(2):156-62. PubMed ID: 20227682
    [Abstract] [Full Text] [Related]

  • 16. Identifying Profiles of Patients With Bipolar I Disorder Who Would Benefit From Maintenance Therapy With a Long-Acting Injectable Antipsychotic.
    Tohen M, Goldberg JF, Hassoun Y, Sureddi S.
    J Clin Psychiatry; 2020 Jun 16; 81(4):. PubMed ID: 32558403
    [Abstract] [Full Text] [Related]

  • 17. All-cause hospitalization and associated costs in patients with schizophrenia or bipolar disorder initiating long-acting injectable antipsychotics.
    Yan T, Greene M, Chang E, Hartry A, Touya M, Broder MS.
    Curr Med Res Opin; 2018 Jan 16; 34(1):41-47. PubMed ID: 29057674
    [Abstract] [Full Text] [Related]

  • 18. Effectiveness of long-acting injectable risperidone versus oral antipsychotics in the treatment of recent-onset schizophrenia: a case-control study.
    Barrio P, Batalla A, Castellví P, Hidalgo D, García M, Ortiz A, Grande I, Pons A, Parellada E.
    Int Clin Psychopharmacol; 2013 Jul 16; 28(4):164-70. PubMed ID: 23587986
    [Abstract] [Full Text] [Related]

  • 19. Long-Acting Injectable Risperidone for Relapse Prevention and Control of Breakthrough Symptoms After a Recent First Episode of Schizophrenia. A Randomized Clinical Trial.
    Subotnik KL, Casaus LR, Ventura J, Luo JS, Hellemann GS, Gretchen-Doorly D, Marder S, Nuechterlein KH.
    JAMA Psychiatry; 2015 Aug 16; 72(8):822-9. PubMed ID: 26107752
    [Abstract] [Full Text] [Related]

  • 20. Long-acting injectable antipsychotics for the maintenance treatment of bipolar disorder.
    Gigante AD, Lafer B, Yatham LN.
    CNS Drugs; 2012 May 01; 26(5):403-20. PubMed ID: 22494448
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 21.